NovaBridge Biosciences (NBP) EBT (2019 - 2025)
NovaBridge Biosciences (NBP) reported EBT of -$72.9 million for Q4 2025, down 571.87% year-over-year from $15.4 million in Q4 2024, and down 967.05% on a QoQ basis from -$6.8 million in Q3 2025.
NovaBridge Biosciences (NBP) has 5 years of EBT data on file, last reported at -$72.9 million in Q4 2025.
- Quarterly EBT fell 571.87% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$88.3 million (down 77.76% YoY) and the FY2025 annual result came in at -$88.3 million, down 77.76% from the prior year.
- EBT declined to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Across five years, EBT topped out at -$3.2 million in Q1 2025 and bottomed at -$72.9 million in Q4 2025.
- The 3-year median for EBT is -$9.4 million (2024), against an average of -$19.2 million.
- The widest annual swing landed in 2024, when EBT surged 70.62%; it then plunged 571.87% in 2025.
- Tracing NBP's EBT over 3 years: stood at -$36.9 million in 2023, then surged by 70.62% to -$10.8 million in 2024, then sank by 571.87% to -$72.9 million in 2025.
- Per Business Quant, the three latest NBP EBT figures stand at -$72.9 million (Q4 2025), -$6.8 million (Q3 2025), and -$5.5 million (Q2 2025).
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -10.84 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Dec 31, 2023 | -36.91 Mn |
| Sep 30, 2023 | -8.22 Mn |
| Jun 30, 2023 | -27.56 Mn |
| Dec 31, 2020 | 159.01 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |